American College of Cardiology Reveals its Late-Breaking Clinical Trial Presentations for 2024
ACC.24 Science Data

The American College of Cardiology has announced a list of 5 late-breaking clinical trials sessions, and 3 featured clinical research sessions to be presented in April. 

ACC.24 will take place from the 6th to the 8th April at the Georgia World Congress Center in Atlanta, GA, US. Access the full programme here. 


Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials

Saturday, April 6 - 9:30 – 10:30 am ET

  • A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients With HFrEF and HFpEF: Principal Results From the RELIEVE-HF Trial – Presented by Dr Gregg W Stone
  • Empagliflozin After Acute Myocardial Infarction: Results of the EMPACT-MI Trial – Presented by Dr Javed Butler
  • CSL112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients With Acute Myocardial Infarction (ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results – Presented by Dr C Michael Gibson


Featured Clinical Research I

Saturday, April 6- 4:15 – 5:30 pm ET


  • Comparison of an "Inclisiran First" Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial – Presented by Dr Michael J Koren
  • Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes – Presented by Dr Brian A Ference
  • Once-weekly Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction, Obesity and Type 2 Diabetes: Main Results From the Step-HFpEF Dm Trial – Presented by Dr Mikhail Kosiborod
  • Mandibular Advancement Device Versus CPAP For Blood Pressure Reduction in Obstructive Sleep Apnea and High Cardiovascular Risk─ A Randomized Clinical Non-inferiority Trial – Presented by Dr Ronald Chi Hang Lee
  • Remote Acute Assessment of Patients With High Cardiovascular Risk Post-acute Coronary Syndrome (TELE-ACS) – Presented by Dr Nasser N Alshahrani


Late-Breaking Clinical Trials II 

Sunday, April 7- 8 – 9:15 am ET


  • Effect of Gamification, Financial Incentives or Both Combined to Increase Physical Activity Among Patients With Elevated Risk For Major Adverse Cardiovascular Events. The Be Active Randomized Clinical Trial – Presented by Dr Alexander Fanaroff
  • Zilebesiran in Combination With a Standard-of-care Antihypertensive in Patients With Inadequately Controlled Hypertension: Primary Results From the Phase 2 Kardia-2 Study – Presented by Dr George L Bakris
  • Efficacy and Safety of Olezarsen in Patients With Hypertriglyceridemia and High Cardiovascular Risk: Primary Results of the BRIDGE-TIMI 73a Trial – Presented by Dr Brian Bergmark
  • Randomized, Double-blind, Placebo-controlled, Phase 3, Study to Evaluate Lerodalcibep Long-term Efficacy and Safety in Patients With, or at Very-high or High Risk, For Cardiovascular Disease on Stable Lipid-lowering Therapy – Presented by Dr Eric Quinton Klug
  • Plozasiran (ARO-APOC3), An Investigational RNAi Therapeutic, Demonstrates Profound and Durable Reductions in APOC-3 and Triglycerides (TG) in Patients With Severe Hypertriglyceridemia (SHTG), SHASTA-2 Final Results – Presented by Dr Daniel Gaudet


Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials III 

Sunday, April 7 - 9:45 – 11 am ET


  • Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized Smart Trial – Presented by Dr Howard C Herrmann
  • Effect of Edetate Disodium Based Chelation Infusions on Cardiovascular Events in Post-MI Patients With Diabetes: The TACT2 Trial – Presented by Dr Gervasio A Lamas
  • Long-term Beta-blocker Treatment After Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction: The REDUCE-AMI Trial – Presented by Dr Troels Yndigegn
  • Percutaneous Transvalvular Micro-axial Flow Pump in Infarct Related Cardiogenic Shock: Results of the Danger-shock Trial – Presented by Dr Jacob Eifer Moller
  • One-month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes: Principal Results From the Double-blind, Placebo-controlled Ultimate DAPT Trial – Presented by Dr Gregg W Stone


Featured Clinical Research II

Sunday, April 7- 12:15 – 1:30 pm ET


  • Benzodiazepine-free Cardiac Anesthesia For Reduction of Postoperative Delirium (B-Free): A Multi-centre Randomized Cluster Crossover Trial – Presented by Dr John Spence
  • The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Study: A Randomized Evaluation of a Team-based Remote Education and Medication Management Program to Reduce CV and Kidney Risk – Presented by Dr Alexander J Blood
  • Improving Cardiac Rehabilitation Participation in Lower-socioeconomic Status Patients: Case Management Vs Financial Incentives – Presented by Dr Diann Gaalema
  • Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic (PRO-HF) Trial – Presented by Dr Amneet Sandhu
  • Restrictive Versus Liberal Blood Transfusion Strategy in Type 1 Versus Type 2 Myocardial Infarction: A Prespecified Subgroup Analysis From the Myocardial Ischemia and Transfusion (MINT) Trial – Presented by Dr Andrew P DeFillipis


Late-Breaking Clinical Trials Deep Dive I 


Sunday, April 7 - 2 – 3:15 pm ET

Further insights from the key clinical trials presented at ACC.2024.


Clinical and Investigative Horizons

Sunday, April 7 - 4:30 – 5:45 pm ET


  • Health 360x Registry: Scalable Workforce For Equitable Access to Point of Care Decentralized Clinical Trials – Presented by Dr Elizabeth Ofili
  • Prevalence of Cardiovascular Disease and Risk Factors Among National Football League Alumni and Their Family Members: Results From the Huddle Study – Michael K Amponsah
  • Hózhó (Heart Failure Optimization at Home to Improve Outcomes): A Pragmatic Clinical Trial of Telephone-based Guideline-directed Medical Therapy Optimization in Navajo Nation – Presented by Dr Lauren Eberley
  • Advancing Acute MI Care in Densely Populated LMICs: Innovative Standalone Chest Pain Units For Expedited Triage and Timely Management – A Role Model For Global Healthcare Systems – Presented by DrNadeem Qamar
  • A Clinical Trial to Evaluate the Influence of a Spirituality Intervention on Blood Pressure Control, Central Hemodynamics and Endothelial Function: The Feel Trial – Presented by Dr Maria Figueiredo Teixeria


Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials IV

Monday, April 8 - 8:30 – 9:45 am ET


  • A Selective Aldose Reductase Inhibitor (at-001) For the Treatment of Diabetic Cardiomyopathy: Primary Results of the Phase 3 Randomized Controlled ARISE-HF Study – Presented by Dr James Januzzi
  • Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results of IMPROVE-HCM – Presented by Dr Martin S Maron
  • Topical Tranexamic Acid to Reduce Seizures in Cardiac Surgery – Presented by Dr Andre Lamy
  • Preventing Cardiac Damage in Patients Treated For Breast Cancer and Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced Cardiotoxicity (PROACT) – Presented by Dr David Austin
  • Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial – Presented by Dr Steven Nissen


Late-Breaking Clinical Trials V

Monday, April 8 - 11 am – 12:15 pm ET


  • Coronary Sinus Reducer For the Treatment of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC) – Presented by Dr Michael Foley
  • Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients at Low to Intermediate Risk: One Year Outcomes of the Randomized DEDICATE-DZHK6 Trial – Presented by Dr Moritz Seiffert
  • Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target Bp I Randomized Trial – Presented by Dr David Kandzari
  • Preventive PCI or Medical Therapy Alone For Atherosclerotic Coronary Vulnerable Plaques – Presented by Dr Seung-Jung Park
  • Comparison of Intravascular Ultrasound-guided Versus Angiography-guided Angioplasty For the Outcomes of Drug-coated Balloon in the Treatment of Femoropopliteal Artery Disease – Presented by Dr Young-Guk Ko


Featured Clinical Research III 

Monday, April 8 - 12:45 – 2 pm ET

Room B406A

  • Fractional Flow Reserve-guided Complete or Culprit-only PCI in Patients With ST-elevation Myocardial Infarction – Presented by Dr Felix Bohm
  • A Multicenter Prospective Randomized Study Comparing the Incidence of Periprocedural Cerebral Embolisms Caused by Catheter Ablation of Atrial Fibrillation Between Cryoballoon and Radiofrequency Ablation – Presented by Dr Kengo Kusano
  • Transseptal Versus Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli (the TRAVERSE Trial) – Presented by Dr Gregory M Marcus
  • Intravascular Ultrasound-guided Versus Angiography-guided Percutaneous Coronary Intervention in Acute Coronary Syndromes: The Multicenter, Randomized, Blinded, IVUS-ACS Trial – Presented by Dr S Chen
  • Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement: The PERFORM-TAVR Trial – Presented by Dr Jonathan Afilalo


Late-Breaking Clinical Trials Deep Dive II

Monday, April 8 - 2:30 – 3:45 pm ET

Further insights from the key clinical trials presented at ACC.2024. Meet the Radcliffe Cardiology team at 3139, Main Exhibition Hall.